Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Neurodegener Dis Manag ; 6(2): 99-105, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27032814

ABSTRACT

BACKGROUND: Gait disorder is very prevalent in multiple sclerosis. After 15 years of disease progression, 50% of patients need assistive devices for walking. MATERIALS & METHODS: We performed a multicenter observational study, including multiple sclerosis patients with an Expanded Disability Status Scale score between 4.0 and 7.0, normal kidney function and no previous history of seizures. RESULTS: The study sample comprised 138 patients with average age of 50.3 years median Expanded Disability Status Scale of 6.0. After treatment, a significant reduction was observed in both the Timed 25-Foot Walk test (baseline, 20.3 s; 14 days, 13.2 s; p < 0.001; 3 months, 12.1 s; p < 0.001) and the 12-Item Multiple Sclerosis Walking Scale score (baseline, 82.3; 14 days, 59.4; p < 0.001; 3 months, 57.2; p < 0.001). Adverse events were recorded in 39.9% of patients.


Subject(s)
4-Aminopyridine/therapeutic use , Gait Disorders, Neurologic/diagnosis , Gait Disorders, Neurologic/drug therapy , Multiple Sclerosis/diagnosis , Multiple Sclerosis/drug therapy , Potassium Channel Blockers/therapeutic use , 4-Aminopyridine/adverse effects , Adult , Aged , Dizziness/chemically induced , Female , Follow-Up Studies , Gait Disorders, Neurologic/epidemiology , Headache/chemically induced , Humans , Male , Middle Aged , Multiple Sclerosis/epidemiology , Potassium Channel Blockers/adverse effects , Treatment Outcome , Walking/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...